Could your own cells fight parkinson? new brain implant trial begins
NCT ID NCT06344026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether implanting a person's own lab-grown dopamine cells into their brain is safe for Parkinson disease. Nine participants aged 40-75 with Parkinson for at least 4 years will receive the injection. The goal is to see if the cells can replace lost dopamine-producing neurons and improve motor symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 9 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2024
- Expected to finish
-
Apr 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 40-75 years of age at time of consent in the trial-ready cohort study ANPD001-01 * Met all eligibility requirements for inclusion in the trial-ready cohort in clinical study ANPD001-01 * Diagnosed with Parkinson Disease at least 4 years ago * Unequivocal motor response to Levodopa Exclusion Criteria: * Prior brain surgery that, in the opinion of the neurologist or neurosurgeon, contraindicates administration of ANPD001 * History of intracranial therapy for PD, including deep brain stimulation (DBS), focused ultrasound (FUS), gene therapy or other biological therapy * History of cognitive impairment or dementia * History of clinically significant Dopa Dysregulation syndrome * History of epilepsy, stroke, multiple sclerosis, poorly controlled or progressive neurological disease (other than PD), or poorly controlled cardiovascular disease * Inability to temporarily stop anticoagulation or antiplatelet therapy for at least 2 weeks * History of malignancy (cerebral or systemic) within the prior 5 years, except treated cutaneous squamous or basal cell carcinomas * Contraindication to MRI / contrast CRT and/or use of contrast agents * Weight \> 300 lbs or Body Mass Index (BMI) \> 35 * Newly diagnosed diabetes (HbA1c \> 7.0%), uncontrolled diabetes \> 8.0% requiring frequent medication changes, or any other acute or chronic medical condition that would significantly increase the risks of a neurosurgical procedure * Pregnancy or lactation * Significant drug-induced dyskinesia (\> 3 for any body part on the Abnormal Involuntary Movement Scale \[AIMS\]) * Male or female with reproductive capacity who is unwilling to use barrier contraception for 3 months post-administration of the investigational product * Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments * Any significant issue raised by the neurologist or neurosurgeon
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
9 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Feinstein Institutes
Manhasset, New York, 11030, United States
-
Scripps Health
La Jolla, California, 92037, United States
-
University of Arizona - Banner Health
Tucson, Arizona, 85724, United States
-
University of California, Irvine
Orange, California, 92868, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Diego
San Diego, California, 92037, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Giving Parkinson's patients a say may boost their Brain's ability to learn movement
- Brain scans probe why some Parkinson's patients freeze Mid-Step
- Can tango rewire the brain? dance program tested for Parkinson's and dementia
- Can a workout after walking practice help Parkinson's patients learn better?